Comparing the Clinical Trials of Baricitinib and Ritlecitinib in Alopecia Areata

In this episode, 'Comparing the Clinical Trials of Baricitinib and Ritlecitinib in Alopecia Areata,' the expert dermatologist explored the following questions:

Baricitinib was the first JAK inhibitor approved in patients with alopecia areata (AA). What were the key safety and efficacy results from these clinical trials?

Ritlecitinib was the second JAK inhibitor approved. How did the trial that led to its approval differ from the baricitinib clinical trials?

The panelist examined the pivotal trial design for baricitinib, which enrolled patients with severe AA — defined as a Scalp Area and Hair Loss Tool (SALT) score greater than 50 — and demonstrated that approximately 30% of patients achieved a SALT score below 20 at 36 weeks on the 4 mg dose, with the 2 mg dose performing substantially lower. Dr. Mostaghimi then outlined the safety profile of baricitinib, noting the class-wide black box warning shared by all JAK inhibitors for thrombosis, malignancy, major adverse cardiac events (MACE), and death, as well as an elevated risk of herpetic infections. Turning to ritlecitinib, he highlighted key differences in trial design, including its Phase 2B/3 structure, a primary endpoint at 24 weeks rather than 36, and the inclusion of adolescents aged 12 to 17 — making ritlecitinib the only FDA-approved option for that age group. He also noted that ritlecitinib's JAK3/TEK mechanism of action results in fewer lipid abnormalities compared with other JAK inhibitors, making it a preferred option for patients with dyslipidemia at baseline.

Throughout the conversation, the expert provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'Deuruxolitinib in Alopecia Areata: Trial Data, Onset of Action, and Adverse Event Management,' features the panelist advances their conversation on alopecia areata and focusing on the clinical trial results for deuruxolitinib, how its faster onset of action informs treatment selection, and practical strategies for monitoring and managing JAK inhibitor adverse events in clinical practice.